SABCS 2025

Important new data for young breast cancer patients

Firstline treatment of MBC: Which strategy is best?

Axilla dissection - less is more

PALLAS trial and ctDNA

SERDs in early breast cancer - the new era has begun?

Revolution in adjuvant endocrine therapy?

AI based prognostic test

Giredestrant will replace current adjuvant therapy

SERDs now in adjuvant therapy

ALTTO trial outcome according to endocrine therapy

Surgery remains soc in low risk EBC

ctDNA analysis could optimize the approach in HER2+

Optimized endocrine therapy for premenopausal patients

Significant innovations in early and metastatic HER2+…

sTILs with deep learning AI

Safety data DB11

Platinum adjuvant in TNBC

In addition to pCR, ctDNA is prognostically relevant…

Carboplatin in adjuvant setting of TNBC

Risultati dello studio ALTTO in base alla terapia…

El análisis del ADN libre circulante podría optimizar…

Otimização da terapia: abordagens endócrinas em…

Carboplatino nel contesto adiuvante del TNBC

SERDy we wczesnym raku piersi -początek nowej epoki?

No improvement over standard therapy

Traditional chemotherapy should not be forgotten as…

Chemotherapy-free treatment: a promising therapeutic…

The significance of SG is more clearly defined

Elacestrant is a good combination partner for HR+ HER2+…

Phase 2 combination of elacestrant with everolimus or…

Triple-positive MBC: less chemotherapy, more endocrine…

Elacestrant as oral endocrine backbone

ASCENT-07 a negative trial

Palbociclib likely delays CNS progression

Make a hot tumor out of a cold tumor

Biomarker and clinical subgroup analysis of evERA…

New evidence for oral SERDs

Maintenance therapy HER2+ Tucatinib as a new option

Monitoring of ILD

ctDNA Dynamics as a biomarker of response

Significant innovations in early and metastatic HER2+…

Tucatinib a new SERD in the adjuvant setting

Jeszcze nie czas na rezygnację z tradycyjnej…

Risultati aggiornati di VIKTORIA-1

Nuove prove a favore dei SERD orali

Résultats actualisés de VIKTORIA-1

Elacestrant come partner endocrino orale

La dinamica del ctDNA come biomarcatore di risposta

Tucatinib, un nouveau SERD dans le cadre d'un…